Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects.
OBJECTIVE
To determine the relevant dose of bendrofluazide for treating mild to moderate hypertension.


METHODS
Double blind parallel group trial of patients who were given placebo for six weeks and then randomly allocated to various doses of bendrofluazide (1.25, 2.5, 5, or 10 mg daily) or placebo for 12 weeks.


METHODS
General practices in Zealand, Denmark.


METHODS
257 Patients with newly diagnosed or previously treated hypertension, aged 25-70, who had a mean diastolic blood pressure of 100-120 mm Hg after receiving placebo for six weeks.


METHODS
Reduction in diastolic blood pressure and changes in biochemical variables (potassium, urate, glucose, fructosamine, total cholesterol, apolipoprotein A I, apolipoprotein B, and triglyceride concentrations).


RESULTS
All doses of bendrofluazide significantly reduced diastolic blood pressure to the same degree (10-11 mm Hg). Clear relations between dose and effect were shown for potassium, urate, glucose, total cholesterol, and apolipoprotein B concentrations. The 1.25 mg dose increased only urate concentrations, whereas the 10 mg dose affected all the above biochemical variables.


CONCLUSIONS
The relevant range of doses of bendrofluazide to treat mild to moderate hypertension is 1.25-2.5 mg a day. Higher doses caused more pronounced adverse biochemical effects including adverse lipid effects. Previous trials with bendrofluazide have used too high doses.
Carlsen
J E
JE
Medicon, København O, Denmark.
Køber
L
L
Torp-Pedersen
C
C
Johansen
P
P
D000328:Adult; D000368:Aged; D001539:Bendroflumethiazide / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008875:Middle Aged; D011379:Prognosis; D011897:Random Allocation
D001539:Bendroflumethiazide